Title: Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20151201
Title: Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.
Journal: Cancer medicine 20150701
Title: Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
Journal: Expert opinion on investigational drugs 20150101
Title: ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
Journal: Clinical advances in hematology & oncology : H&O 20140701
Title: Ardini E, et al. Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications. Mol Cancer Ther. 2016 Apr;15(4):628-39.
Title: Iyer R, et al. Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model. Cancer Lett. 2016 Mar 28;372(2):179-86.
